Redbiotec Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $10M
Latest Deal Amount
  • Investors
  • 9

Redbiotec General Information

Description

Developer of prophylactic vaccines intended to be used as an immunotherapeutic drug against Herpes and Cancer. The company's vaccines are made with using proprietary co-expression technology to create virus-like particles utilized in its vaccines and focuses on viral targets, including RSV, HCV, dengue, influenza and HPV, enabling cancer patients to get cured.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Wagistrasse 23
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

Redbiotec Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Redbiotec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A) 14-Dec-2020 $10M 000.00 Completed Generating Revenue
10. Later Stage VC 11-Dec-2019 00.000 000.00 0000 Completed Generating Revenue
9. Later Stage VC 30-May-2017 00.000 000.00 000.00 Completed Generating Revenue
8. Later Stage VC 10-Jun-2016 00.000 000.00 000.00 Completed Generating Revenue
7. Later Stage VC 21-Jul-2015 00.000 000.00 000.00 Completed Generating Revenue
6. Later Stage VC 04-Nov-2014 00.000 0000 0000 Completed Generating Revenue
5. Later Stage VC 04-Dec-2013 00.000 000.00 0000 Completed Generating Revenue
4. Grant 23-Oct-2013 00.000 00.000 Completed Generating Revenue
3. Later Stage VC 08-Dec-2011 $3.34M $6.86M 0000 Completed Generating Revenue
2. Early Stage VC 20-Apr-2010 $1.37M $3.52M 000.00 Completed Startup
To view Redbiotec’s complete valuation and funding history, request access »

Redbiotec Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 000.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 000.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 0,000 000.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 0,000 000.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 0,000 000.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 00,000 000.000000 00000.00 00000.00 00 00000.00 00.000
Ordinary 000 000.000000 00000.00 00000.00 00 00000.00 0.00
Ordinary 0,000 000.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 1,654 $10.076460 $364.77 $364.77 1x $364.77 3.82%
Ordinary 2,055 $10.076460 $367.79 $367.79 1x $367.79 4.74%
To view Redbiotec’s complete cap table history, request access »

Redbiotec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of prophylactic vaccines intended to be used as an immunotherapeutic drug against Herpes and Cancer. The compa
Drug Discovery
Schlieren, Switzerland
16 As of 2021
000.00
00000000000 000.00

00000000

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore m
0000 000000000
Schlieren, Switzerland
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

00000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
Schlieren, Switzerland
0 As of 0000
00.000
0.000 0000-00-00
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Redbiotec Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GlycoVaxyn Formerly VC-backed Schlieren, Switzerland 00 000.00 000000&0 000.00
00000000 Venture Capital-Backed Schlieren, Switzerland 0 00.000 0000000000 0 00.000
0000000 Venture Capital-Backed Wuppertal, Germany 00 000.00 0000000000 000.00
0000 Accelerator/Incubator Backed Lausanne, Switzerland 00 000.00 0000000000 000.00
To view Redbiotec’s complete competitors history, request access »

Redbiotec Executive Team (8)

Name Title Board Seat Contact Info
Christian Schaub Co-Founder, Chief Executive Officer, President & Chairman
Corinne John Ph.D Co-Founder, Board Member, Chief Technology Officer & Executive Vice President
Sabine Wellnitz Ph.D Executive Vice President
David Joe Owner
Lbachir BenMohamed Advisor
You’re viewing 5 of 8 executive team members. Get the full list »

Redbiotec Board Members (3)

Name Representing Role Since
Hans-Peter Richard Self Board Member 000 0000
Michael Sidler Ph.D Redalpine Venture Partners Board Member 000 0000
Winfried Mayer Ph.D Self Board Member 000 0000
To view Redbiotec’s complete board members history, request access »

Redbiotec Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Redbiotec Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Vaccine Initiative Government 000 0000 000000 0
BioBac Angel Group Minority 000 0000 000000 0
Hans-Peter Richard Angel (individual) Minority 000 0000 000000 0
Nallai Wickreman Angel (individual) Minority 000 0000 000000 0
Paul Peyrot Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »